During a live event, Andrew H. Lipsky, MD, and participants discussed balancing efficacy, safety, and patient preferences ...

Over the coming years, the Inflation Reduction Act aims to help those with Medicare save on their prescription drug costs. Learn more.

Over the coming years, the Inflation Reduction Act aims to save people with Medicare money on their prescription medications. Read more.

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on ...

CMS proposes the 2026 Physician Fee Schedule (PFS), addressing payment disparities in oncology, but the community oncology ...

Shares of clinical-stage company Summit Therapeutics SMMT rose nearly 9% on Thursday following a report issued by Bloomberg, ...

AstraZeneca (AZ) has announced that its fixed-duration Calquence (acalabrutinib)-based regimens have been approved by the European Commission (EC) to treat chronic lymphocytic leukaemia (CLL) in the ...

Calquence is not currently approved for the treatment of MCL in Japan. As part of an extensive clinical development programme, Calquence is currently being evaluated as a single treatment and in ...

Calquence is not currently approved for the treatment of MCL in Japan. As part of an extensive clinical development programme, Calquence is currently being evaluated as a single treatment and in ...

The FDA has approved Calquence® in combination with bendamustine and rituximab for the treatment of adults with previously untreated MCL.

AstraZeneca’s CALQUENCE®(acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously ...

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma ...